Serum Free Light Chain Assays (sFLC) Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032
Growth Serum Free Light Chain (sFLC) Assays Market
The serum free light chain (sFLC) assays market size was valued at USD 227.2 billion in 2023, and the market is now projected to grow from USD 245.8 billion in 2024 to USD 477.3 billion by 2032, exhibiting a CAGR of 8.6% during the forecast period of 2024-2032.
The COVID-19 pandemic induced a temporary slowdown in the global market growth of serum loose mild chain (sFLC) assays in 2020 due to reduced cancer checking out volumes amid travel restrictions. Major players experienced sales declines as demand waned in hospitals and scientific laboratories. However, the resurgence of affected person visits for diagnostic screenings, specifically for continual issues like multiple myeloma, fueled marketplace growth in 2021.
The global incidence of multiple myeloma is at the rise due to growing causative danger factors like old age, circle of relative’s history, radiation publicity, and other plasma mobile problems along with solitary plasmacytoma the various populace.
The attention is transferring towards loose mild chain checks over conventional techniques like serum and urine protein electrophoresis for diagnosing and tracking monoclonal gammopathies. Traditional strategies, although useful, can be insensitive in detecting and quantifying free mild chains, necessitating greater advanced techniques like mass spectrometry for accurate prognosis, specifically in light chain amyloidosis and light chain deposition ailment.
Comprehensive Analysis of Serum Free Light Chain (sFLC) Assays Market
The serum free light chain (sFLC) assays market growth is rising at an exponential rate due to its market segmentation. This market expansion effectively provides a detailed regional assessments considering the dominant supply and demand forces that impact the industry. These segmentations are methodically segregated by technique analysis, by indication analysis, by end-user analysis. By technique analysis incudes, latex nephelometric/turbiometric and ELISA. By indication analysis incudes, multiple myeloma, light chain amyloidosis, and others. By end-user analysis incudes hospital laboratories, clinical & pathology laboratories, and others.
The North America region lead the serum free light chain (sFLC) assays market share by benefitting a market size of USD 113.3 billion in 2023 due to the rising adoption of serum free light chain screenings among the patient population in the region.
The top players in the market play a crucial role in the industry assuring market growth and setting market standards. These players include, Thermo Fisher Scientific Inc., Siemens Healthineers AG, Sebia, Diazyme Laboratories, Inc these market players provide a level-playing competitive landscape.
In August 2022, The Human Kappa Free Light Chain Assay by Diazyme Laboratories, Inc. received FDA premarket notification for quantitative determination of Kappa Free Light Chain (FLC) concentration in serum on validated analyzers, including Beckman Coulter UniCel DxC 800 Synchron, in 2019.
Segmentation Table
Attribute Details
Study Period 2019-2032
Base Year 2023
Estimated Year 2024
Forecast Period 2024-2032
Historical Period 2019-2022
Unit Value (USD Million)
Growth Rate CAGR of 8.6% from 2024-2032
Segmentation By Technique
Latex Nephelometric/Turbiometric
ELISA
By Indication
Multiple Myeloma
Light Chain Amyloidosis
Others
By End User
Hospital Laboratories
Clinical & Pathology Laboratories
Others
By Region
North America (By Technique, Indication, End-user, and Country)
U.S.
Canada
Europe (By Technique, Indication, End-user, and Country)
U.K.
Germany
France
Spain
Italy
Scandinavia
Rest of Europe
Asia Pacific (By Technique, Indication, End-user, and Country)
Japan
China
India
Australia
Southeast Asia
Rest of Asia Pacific
Rest of the World (By Technique, Indication, and End-user)
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 2. Executive Summary
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
- 4. Key Insights
- 4.1. Prevalence of Multiple Myeloma, by Key Countries, 2023
- 4.2. Technological Advancements in Serum Free Light Chain Assay (sFLC)
- 4.3. Key Industry Developments Mergers, Acquisitions & partnerships
- 4.4. Impact of COVID-19 on the Market
- 5. Global Serum Free Light Chain (sFLC) Assays Market Analysis, Insights and Forecast, 2019-2032
- 5.1. Market Analysis, Insights and Forecast – By Technique
- 5.1.1. Latex Nephelometric/Turbidometric
- 5.1.2. ELISA
- 5.2. Market Analysis, Insights and Forecast – By Indication
- 5.2.1. Multiple Myeloma
- 5.2.2. Light Chain Amyloidosis
- 5.2.3. Others
- 5.3. Market Analysis, Insights and Forecast – By End User
- 5.3.1. Hospital Laboratories
- 5.3.2. Clinic & Pathology Laboratories
- 5.3.3. Others
- 5.4. Market Analysis, Insights and Forecast – By Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Rest of the World
- 6. North America Serum Free Light Chain (sFLC) Assays Market Analysis, Insights and Forecast, 2019-2032
- 6.1. Market Analysis, Insights and Forecast – By Technique
- 6.1.1. Latex Nephelometric/Turbidometric
- 6.1.2. ELISA
- 6.2. Market Analysis, Insights and Forecast – By Indication
- 6.2.1. Multiple Myeloma
- 6.2.2. Light Chain Amyloidosis
- 6.2.3. Others
- 6.3. Market Analysis, Insights and Forecast – By End User
- 6.3.1. Hospital Laboratories
- 6.3.2. Clinic & Pathology Laboratories
- 6.3.3. Others
- 6.4. Market Analysis, Insights and Forecast – By Country
- 6.4.1. U.S.
- 6.4.2. Canada
- 7. Europe Serum Free Light Chain (sFLC) Assays Market Analysis, Insights and Forecast, 2019-2032
- 7.1. Market Analysis, Insights and Forecast – By Technique
- 7.1.1. Latex Nephelometric/Turbidometric
- 7.1.2. ELISA
- 7.2. Market Analysis, Insights and Forecast – By Indication
- 7.2.1. Multiple Myeloma
- 7.2.2. Light Chain Amyloidosis
- 7.2.3. Others
- 7.3. Market Analysis, Insights and Forecast – By End User
- 7.3.1. Hospital Laboratories
- 7.3.2. Clinic & Pathology Laboratories
- 7.3.3. Others
- 7.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 7.4.1. U.K.
- 7.4.2. Germany
- 7.4.3. France
- 7.4.4. Spain
- 7.4.5. Italy
- 7.4.6. Scandinavia
- 7.4.7. Rest of Europe
- 8. Asia Pacific Serum Free Light Chain (sFLC) Assays Market Analysis, Insights and Forecast, 2019-2032
- 8.1. Market Analysis, Insights and Forecast – By Technique
- 8.1.1. Latex Nephelometric/Turbidometric
- 8.1.2. ELISA
- 8.2. Market Analysis, Insights and Forecast – By Indication
- 8.2.1. Multiple Myeloma
- 8.2.2. Light Chain Amyloidosis
- 8.2.3. Others
- 8.3. Market Analysis, Insights and Forecast – By End User
- 8.3.1. Hospital Laboratories
- 8.3.2. Clinic & Pathology Laboratories
- 8.3.3. Others
- 8.4. Market Analysis, Insights and Forecast – By Country/ Sub-region
- 8.4.1. Japan
- 8.4.2. China
- 8.4.3. India
- 8.4.4. Australia
- 8.4.5. Southeast Asia
- 8.4.6. Rest of Asia Pacific
- 9. Rest of the World Serum Free Light Chain (sFLC) Assays Market Analysis, Insights and Forecast, 2019-2032
- 9.1. Market Analysis, Insights and Forecast – By Technique
- 9.1.1. Latex Nephelometric/Turbidometric
- 9.1.2. ELISA
- 9.2. Market Analysis, Insights and Forecast – By Indication
- 9.2.1. Multiple Myeloma
- 9.2.2. Light Chain Amyloidosis
- 9.2.3. Others
- 9.3. Market Analysis, Insights and Forecast – By End User
- 9.3.1. Hospital Laboratories
- 9.3.2. Clinic & Pathology Laboratories
- 9.3.3. Others
- 10. Competitive Analysis
- 10.1. Global Market Share Analysis (2023)
- 10.2. Company Profiles
- 10.2.1. Thermo Fisher Scientific Inc.
- 10.2.1.1. Overview
- 10.2.1.2. Product
- 10.2.1.3. SWOT Analysis
- 10.2.1.4. Recent Developments
- 10.2.1.5. Strategies
- 10.2.1.6. financials (Based on Availability)
- 10.2.2. Siemens Healthineers AG
- 10.2.2.1. Overview
- 10.2.2.2. Product
- 10.2.2.3. SWOT Analysis
- 10.2.2.4. Recent Developments
- 10.2.2.5. Strategies
- 10.2.2.6. financials (Based on Availability)
- 10.2.3. Sebia
- 10.2.3.1. Overview
- 10.2.3.2. Product
- 10.2.3.3. SWOT Analysis
- 10.2.3.4. Recent Developments
- 10.2.3.5. Strategies
- 10.2.3.6. financials (Based on Availability)
- 10.2.4. Diazyme Laboratories, Inc.
- 10.2.4.1. Overview
- 10.2.4.2. Product
- 10.2.4.3. SWOT Analysis
- 10.2.4.4. Recent Developments
- 10.2.4.5. Strategies
- 10.2.4.6. financials (Based on Availability)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook